OnePath® Access & Support
Takeda's OnePath® program offers personalized product support services to your eligible patients on Takeda HAE treatment. Upon enrollment in OnePath, your patients are connected to a dedicated Patient Support Manager (PSM) who can assist them by:
- Providing important and helpful information about FIRAZYR and other Takeda HAE products that are part of their treatment plan
- Facilitating an insurance benefits investigation, and explaining insurance coverage and financial assistance options (if applicable)
- Connecting patients and their caregiver(s) with educational resources and the OnePath Mobile App at no cost
- Arranging in-home injection training for FIRAZYR available at no cost
Patients enrolled in OnePath may use the OnePath Mobile App to connect with OnePath and track their health in a personal eDiary.
Begin therapy with OnePath
Sign Up
All it takes is for you and your eligible patients to complete the downloadable OnePath Start Form. The OnePath Start Form also serves as the prescription.
Patient Support Manager
A Patient Support Manager initiates a benefits investigation and helps provide information about the prior authorization process (if applicable) and financial assistance options (if needed).
Product Access and Support
A Patient Support Manager sets up FIRAZYR shipment with a specialty pharmacy, coordinates injection training with nurse educators, if requested, and serves as an ongoing resource for your patients' product support needs.
Getting your patients started on FIRAZYR with OnePath
Download the Start Form for FIRAZYR.
Complete and fax the OnePath Start Form for FIRAZYR to 1-855-ONEPATH (1-855-663-7284).
To enroll your patients completely online, visit the new HAE Enrollment portal.
Note that insurance companies sometimes require additional documentation to authorize coverage for FIRAZYR, which could include:
Sample Letter of Medical Necessity
Statement of Medical Necessity
Sample Letter of Intent to Treat
Sample Formulary Exception Letter
FIRAZYR is indicated for the treatment of acute attacks of hereditary angiodema (HAE) in adults 18 years of age or older.
